Friday, July 10, 2026

pharma · Not applicable, Healthy Volunteers · advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

mAbxience

mAbxience clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

madrid, ES HQ
2009 Founded
1,194 Employees
EMA registrant Type
Company details
Status
Public
HQ
madrid, ES
Founded
2009
Employees
1,194
Programs
5
Drugs
10
Patents
0
Intelligence · Clinical Programs

mAbxience projects

3 ClinicalTrials.gov programs sponsored by mAbxience.

mAbxience has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. MB04-C-01-23

    Mabxience Research SL

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial
  2. MB11-C-01-25

    Mabxience Research SL

    Previously Untreated Advanced (Unresectable or Metastatic) Melanoma

    phase 3 small molecule active

    1 trial
  3. MB12-C-02-24

    Mabxience Research SL

    advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

Frequently asked questions

How many clinical projects does mAbxience have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.